KIDS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OrthoPediatrics Corp (KIDS) is not a strong buy for a beginner, long-term investor at this time. While the company shows promising growth potential and has positive analyst sentiment, the current technical indicators, financial performance, and stock trend suggest a cautious approach. The stock is trading near a key pivot point, and there is no immediate signal from proprietary trading tools or options data to suggest a strong entry point.
The MACD is positive but contracting, RSI is neutral at 48.383, and moving averages are converging, indicating no clear trend. The stock is near its pivot point of 17.884, with resistance at 19.591 and support at 16.176. The technical indicators suggest a lack of strong momentum in either direction.
Hedge funds are increasing their positions, with a 114.29% increase in buying activity last quarter.
Analysts have raised price targets, with several maintaining Buy ratings and projecting price targets between $20 and $
The company achieved its first positive free cash flow of $10 million in Q4 2025 and launched innovative products like the 3P Hip and VerteGlide, which could drive future growth.
The stock trend analysis shows a 70% chance of declining by -0.96% in the next day, -1.91% in the next week, and -7.16% in the next month.
Financial performance shows a drop in net income (-37.13% YoY) and EPS (-37.68% YoY) despite revenue growth.
No significant insider trading activity or congress trading data to support bullish sentiment.
In Q4 2025, revenue increased by 16.97% YoY to $61.6 million, and gross margin improved to 73.22% (up 8.43% YoY). However, net income dropped by 37.13% YoY to -$10.1 million, and EPS declined by 37.68% YoY to -0.43. The company achieved positive free cash flow of $10 million, indicating operational improvements but still faces profitability challenges.
Analyst sentiment is positive, with multiple Buy ratings and price targets ranging from $20 to $24. Analysts highlight the company's leadership in pediatric orthopedics, solid Q4 EBITDA, and potential for sustained low-double-digit revenue growth. However, some analysts maintain a Hold rating due to valuation concerns.
